Imatinib latest price in 2024

Imatinib (Imatinib) is an oral tyrosine kinase inhibitor mainly used to treat chronic myelogenous leukemia (CML) and gastrointestinal stromal tumor (GIST). Its working mechanism is to selectively inhibit the activity of BCR-ABL tyrosine kinase and block the signal transmission of this abnormal protein in cancer cells, thereby inhibiting the growth and proliferation of tumor cells. Imatinib is a representative drug for targeted therapy and is hailed as a breakthrough in the field of anti-cancer. Especially its application in CML patients has significantly prolonged the patient's survival and improved the quality of life.

The research and development of imatinib made significant progress in the 20century1990s and was first approved in the United States in 2001. Since then, imatinib has been rapidly promoted globally and has been launched in many countries and regions, becoming an important treatment option for patients with chronic myelogenous leukemia and specific types of gastrointestinal stromal tumors.

in the country, imatinib has been on the market for many years and has been included in the national medical insurance directory. This reduces the drug burden for the majority of patients, especially those with chronic myelogenous leukemia. Taking the common specifications 100mg*60 capsules in the domestic market as an example, the price is about 600 to 700. The actual price varies slightly depending on the region and hospital. For the specific situation of medical insurance reimbursement, it is recommended that patients consult the local hospital pharmacy or medical insurance department, because the medical insurance policies in different regions will be different, and the reimbursement ratio and method will also be different.

In addition to domestically produced imatinib generics, foreign generics, especially those from India, are also quite attractive. The price of generic drugs in India is relatively low. The price of imatinib generic drugs with specifications of 100mg*120 tablets is about 300-400 yuan. The low price of generic drugs in India is mainly due to its lower production costs and loose patent system, which allows generic drugs to enter the market earlier. This provides an affordable alternative to many patients who cannot afford high-priced genuine drugs. However, when choosing Indian generic drugs, patients need to ensure that the drugs come from regular sources and are used under the guidance of a doctor.